Limits...
Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.

Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC - Mol. Cancer (2010)

Bottom Line: Furthermore, no patient with NMIBC in the good-prognosis signature group experienced cancer progression.We identified progression-related gene classifier that has strong predictive value for determining disease outcome in NMIBC.This gene classifier could assist in selecting NMIBC patients who might benefit from more aggressive therapeutic intervention or surveillance.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Urology, College of Medicine, Chungbuk National University, Chungbuk, South Korea. wjkim@chungbuk.ac.kr

ABSTRACT

Background: While several molecular markers of bladder cancer prognosis have been identified, the limited value of current prognostic markers has created the need for new molecular indicators of bladder cancer outcomes. The aim of this study was to identify genetic signatures associated with disease prognosis in bladder cancer.

Results: We used 272 primary bladder cancer specimens for microarray analysis and real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis. Microarray gene expression analysis of randomly selected 165 primary bladder cancer specimens as an original cohort was carried out. Risk scores were applied to stratify prognosis-related gene classifiers. Prognosis-related gene classifiers were individually analyzed with tumor invasiveness (non-muscle invasive bladder cancer [NMIBC] and muscle invasive bladder cancer [MIBC]) and prognosis. We validated selected gene classifiers using RT-PCR in the original (165) and independent (107) cohorts. Ninety-seven genes related to disease progression among NMIBC patients were identified by microarray data analysis. Eight genes, a progression-related gene classifier in NMIBC, were selected for RT-PCR. The progression-related gene classifier in patients with NMIBC was closely correlated with progression in both original and independent cohorts. Furthermore, no patient with NMIBC in the good-prognosis signature group experienced cancer progression.

Conclusions: We identified progression-related gene classifier that has strong predictive value for determining disease outcome in NMIBC. This gene classifier could assist in selecting NMIBC patients who might benefit from more aggressive therapeutic intervention or surveillance.

Show MeSH

Related in: MedlinePlus

Study design and validation strategies.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2821358&req=5

Figure 1: Study design and validation strategies.

Mentions: Table 1 shows the baseline characteristics of the case subjects. We used random computer-generated numbers to assign specimens from 272 consecutive, histologically-verified transitional cell carcinomas in primary bladder cancer patients. To reduce confounding factors for affecting the analyses, any patients diagnosed with concomitant carcinoma in situ (CIS) lesion or only CIS lesion were excluded. For the original cohort, we studied the frozen specimens of bladder cancer tissue from 165 randomly selected patients who had undergone surgical resection of a transitional cell carcinoma at the Chungbuk National University Hospital. The mean follow-up period for the original cohort was 48 months (median 37 months; range, 1-137 months). To independently validate our risk-prediction model, 107 randomly selected primary bladder cancer patients who had similar clinico-pathological characteristics and had undergone surgical resection of a transitional cell carcinoma at the same hospital were used as an independent cohort. The mean follow-up period for the independent cohort was 43 months (median, 26 months; range, 1-194 months). The study design and validation strategy are shown in Fig. 1.


Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.

Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC - Mol. Cancer (2010)

Study design and validation strategies.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2821358&req=5

Figure 1: Study design and validation strategies.
Mentions: Table 1 shows the baseline characteristics of the case subjects. We used random computer-generated numbers to assign specimens from 272 consecutive, histologically-verified transitional cell carcinomas in primary bladder cancer patients. To reduce confounding factors for affecting the analyses, any patients diagnosed with concomitant carcinoma in situ (CIS) lesion or only CIS lesion were excluded. For the original cohort, we studied the frozen specimens of bladder cancer tissue from 165 randomly selected patients who had undergone surgical resection of a transitional cell carcinoma at the Chungbuk National University Hospital. The mean follow-up period for the original cohort was 48 months (median 37 months; range, 1-137 months). To independently validate our risk-prediction model, 107 randomly selected primary bladder cancer patients who had similar clinico-pathological characteristics and had undergone surgical resection of a transitional cell carcinoma at the same hospital were used as an independent cohort. The mean follow-up period for the independent cohort was 43 months (median, 26 months; range, 1-194 months). The study design and validation strategy are shown in Fig. 1.

Bottom Line: Furthermore, no patient with NMIBC in the good-prognosis signature group experienced cancer progression.We identified progression-related gene classifier that has strong predictive value for determining disease outcome in NMIBC.This gene classifier could assist in selecting NMIBC patients who might benefit from more aggressive therapeutic intervention or surveillance.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Urology, College of Medicine, Chungbuk National University, Chungbuk, South Korea. wjkim@chungbuk.ac.kr

ABSTRACT

Background: While several molecular markers of bladder cancer prognosis have been identified, the limited value of current prognostic markers has created the need for new molecular indicators of bladder cancer outcomes. The aim of this study was to identify genetic signatures associated with disease prognosis in bladder cancer.

Results: We used 272 primary bladder cancer specimens for microarray analysis and real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis. Microarray gene expression analysis of randomly selected 165 primary bladder cancer specimens as an original cohort was carried out. Risk scores were applied to stratify prognosis-related gene classifiers. Prognosis-related gene classifiers were individually analyzed with tumor invasiveness (non-muscle invasive bladder cancer [NMIBC] and muscle invasive bladder cancer [MIBC]) and prognosis. We validated selected gene classifiers using RT-PCR in the original (165) and independent (107) cohorts. Ninety-seven genes related to disease progression among NMIBC patients were identified by microarray data analysis. Eight genes, a progression-related gene classifier in NMIBC, were selected for RT-PCR. The progression-related gene classifier in patients with NMIBC was closely correlated with progression in both original and independent cohorts. Furthermore, no patient with NMIBC in the good-prognosis signature group experienced cancer progression.

Conclusions: We identified progression-related gene classifier that has strong predictive value for determining disease outcome in NMIBC. This gene classifier could assist in selecting NMIBC patients who might benefit from more aggressive therapeutic intervention or surveillance.

Show MeSH
Related in: MedlinePlus